These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 20598155)
41. Transcriptional blocks limit adenoviral replication in primary ovarian tumor. Preuss MA; Lam JT; Wang M; Leath CA; Kataram M; Mahasreshti PJ; Alvarez RD; Curiel DT Clin Cancer Res; 2004 May; 10(9):3189-94. PubMed ID: 15131060 [TBL] [Abstract][Full Text] [Related]
42. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
43. Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Doloff JC; Waxman DJ; Jounaidi Y Hum Gene Ther; 2008 Dec; 19(12):1383-400. PubMed ID: 18771358 [TBL] [Abstract][Full Text] [Related]
44. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity. Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459 [TBL] [Abstract][Full Text] [Related]
45. Silencing Daxx increases the anti-tumor activity of a TRAIL/shRNA Bcl-xL-expressing oncolytic adenovirus through enhanced viral replication and cellular arrest. Kang S; Kang D; Bakhtiar Ul Islam SM; Je S; Kim JH; Song JJ Cell Signal; 2015 Jun; 27(6):1214-24. PubMed ID: 25748050 [TBL] [Abstract][Full Text] [Related]
46. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Doloff JC; Jounaidi Y; Waxman DJ Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021 [TBL] [Abstract][Full Text] [Related]
47. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Strauss R; Sova P; Liu Y; Li ZY; Tuve S; Pritchard D; Brinkkoetter P; Möller T; Wildner O; Pesonen S; Hemminki A; Urban N; Drescher C; Lieber A Cancer Res; 2009 Jun; 69(12):5115-25. PubMed ID: 19491256 [TBL] [Abstract][Full Text] [Related]
48. E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2. Akli S; Zhan S; Abdellatif M; Schneider MD Circ Res; 1999 Aug; 85(4):319-28. PubMed ID: 10455060 [TBL] [Abstract][Full Text] [Related]
49. Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Takakura M; Nakamura M; Kyo S; Hashimoto M; Mori N; Ikoma T; Mizumoto Y; Fujiwara T; Urata Y; Inoue M Cancer Gene Ther; 2010 Jan; 17(1):11-9. PubMed ID: 19662088 [TBL] [Abstract][Full Text] [Related]
50. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Heise C; Hermiston T; Johnson L; Brooks G; Sampson-Johannes A; Williams A; Hawkins L; Kirn D Nat Med; 2000 Oct; 6(10):1134-9. PubMed ID: 11017145 [TBL] [Abstract][Full Text] [Related]
51. Deletion analysis of Ad5 E1a transcriptional control region: impact on tumor-selective expression of E1a and E1b. Hedjran F; Shantanu K; Tony R Cancer Gene Ther; 2011 Oct; 18(10):717-23. PubMed ID: 21818136 [TBL] [Abstract][Full Text] [Related]
52. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Tsuruta Y; Pereboeva L; Breidenbach M; Rein DT; Wang M; Alvarez RD; Siegal GP; Dent P; Fisher PB; Curiel DT Clin Cancer Res; 2008 Jun; 14(11):3582-8. PubMed ID: 18519792 [TBL] [Abstract][Full Text] [Related]
53. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA. Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241 [TBL] [Abstract][Full Text] [Related]
55. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142 [TBL] [Abstract][Full Text] [Related]
56. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Kim J; Kim JH; Choi KJ; Kim PH; Yun CO Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410 [TBL] [Abstract][Full Text] [Related]
57. MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Zhang Z; Zhang X; Newman K; Liu X; Seth P Mol Cancer Ther; 2012 Nov; 11(11):2410-8. PubMed ID: 22914437 [TBL] [Abstract][Full Text] [Related]
58. NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Leung EYL; Ennis DP; Kennedy PR; Hansell C; Dowson S; Farquharson M; Spiliopoulou P; Nautiyal J; McNamara S; Carlin LM; Fisher K; Davis DM; Graham G; McNeish IA Mol Ther Oncolytics; 2020 Mar; 16():289-301. PubMed ID: 32195317 [TBL] [Abstract][Full Text] [Related]
59. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. Zheng X; Rao XM; Snodgrass CL; McMasters KM; Zhou HS Cancer Gene Ther; 2006 Jun; 13(6):572-83. PubMed ID: 16341141 [TBL] [Abstract][Full Text] [Related]
60. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model. Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]